相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors
Geraldine M. Ferron et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Secondary and tertiary sulfonamides: a patent review (2008-2012)
Andrea Scozzafava et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells
Xiaolei Wang et al.
PLOS ONE (2013)
Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
Andrea E. Prota et al.
SCIENCE (2013)
Beyond taxanes: the next generation of microtubule-targeting agents
Javier Cortes et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
S. McMeekin et al.
BRITISH JOURNAL OF CANCER (2012)
Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
T. M. Beer et al.
BRITISH JOURNAL OF CANCER (2012)
The Tubulin Colchicine Domain: a Molecular Modeling Perspective
Alberto Massarotti et al.
CHEMMEDCHEM (2012)
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Dan M. Patterson et al.
CLINICAL CANCER RESEARCH (2012)
Novel Drugs Targeting Microtubules: the Role of Epothilones
Gabriella Ferrandina et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Antimitotic Inhibitors
Susana M. Campos et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors
Razelle Kurzrock et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts
Li Liu et al.
PLOS ONE (2012)
An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
Yan Lu et al.
PHARMACEUTICAL RESEARCH (2012)
The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Dietmar W. Siemann
CANCER TREATMENT REVIEWS (2011)
Hallmarks of Molecular Action of Microtubule Stabilizing Agents EFFECTS OF EPOTHILONE B, IXABEPILONE, PELORUSIDE A, AND LAULIMALIDE ON MICROTUBULE CONFORMATION
Marina Khrapunovich-Baine et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
What tubulin drugs tell us about microtubule structure and dynamics
Linda A. Amos
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2011)
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
R. C. DeConti et al.
BRITISH JOURNAL OF CANCER (2010)
Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model
Cheng-Huang Shen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Discovery and Characterization of the Laulimalide-Microtubule Binding Mode by Mass Shift Perturbation Mapping
Melissa J. Bennett et al.
CHEMISTRY & BIOLOGY (2010)
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors
R. L. Oostendorp et al.
INVESTIGATIONAL NEW DRUGS (2010)
The Assembly-Inducing Laulimalide/Peloruside A Binding Site on Tubulin: Molecular Modeling and Biochemical Studies with [3H]Peloruside A
Tam Luong Nguyen et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Microtubule-Binding Natural Products for Cancer Therapy
Qing-Xi Yue et al.
PLANTA MEDICA (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
Nobuyuki Yamamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Indibulin, a Novel Microtubule Inhibitor, Discriminates between Mature Neuronal and Nonneuronal Tubulin
Anke Wienecke et al.
CANCER RESEARCH (2009)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
Vascular targeted therapies in oncology
Dietmar W. Siemann et al.
CELL AND TISSUE RESEARCH (2009)
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Dietmar W. Siemann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
AVE8062: a new combretastatin derivative vascular disrupting agent
Angelo Delmonte et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Possible binding site for paclitaxel at microtubule pores
Matteo Magnani et al.
FEBS JOURNAL (2009)
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
Chryso Kanthou et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
Tubulin-Interactive Natural Products as Anticancer Agents
David G. I. Kingston
JOURNAL OF NATURAL PRODUCTS (2009)
BAL27862: A novel anticancer agent which dissociates microtubules and creates a distinct cellular phenotype
Felix Bachmann et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin
Galina Kuznetsov et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Edith A. Perez
MOLECULAR CANCER THERAPEUTICS (2009)
Anticancer strategies involving the vasculature
Victoria L. Heath et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
V. Dieras et al.
ANNALS OF ONCOLOGY (2008)
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
L. Paz-Ares et al.
BRITISH JOURNAL OF CANCER (2008)
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2
A. Regina et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Microtubule Active Agents: Beyond the Taxane Frontier
Patrick G. Morris et al.
CLINICAL CANCER RESEARCH (2008)
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2008)
Antimitotic and antiproliferative activities of chalcones: Forward structure-activity relationship
Ahcene Boumendjel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Corey J. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M. Mauer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin
Bhabatarak Bhattacharyya et al.
MEDICINAL RESEARCH REVIEWS (2008)
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
I. E. L. M. Kuppens et al.
INVESTIGATIONAL NEW DRUGS (2007)
Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly
Ernest Hamel et al.
MOLECULAR PHARMACOLOGY (2006)
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
Howard W. Salmon et al.
CLINICAL CANCER RESEARCH (2006)
Biological evaluation of tubulysin A:: a potential anticancer and antiangiogenic natural product
Gurmeet Kaur et al.
BIOCHEMICAL JOURNAL (2006)
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
KR Hande et al.
CLINICAL CANCER RESEARCH (2006)
Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria
MW Khalil et al.
CHEMBIOCHEM (2006)
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
KWL Yee et al.
CLINICAL CANCER RESEARCH (2005)
Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization
JM Langenhan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Vascular targeting agents as cancer therapeutics
PE Thorpe
CLINICAL CANCER RESEARCH (2004)
Combretastatin A4 phosphate: background and current clinical status
SL Young et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents
JP Liou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Peloruside A does not bind to the taxoid site on β-tubulin and retains its activity in multidrug-resistant cell lines
TN Gaitanos et al.
CANCER RESEARCH (2004)
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo
CC Kuo et al.
CANCER RESEARCH (2004)
Laulimalide and paclitaxel: A comparison of their effects on tubulin assembly and their synergistic action when present simultaneously
EJ Gapud et al.
MOLECULAR PHARMACOLOGY (2004)
Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine
O Pineda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Microtubule-stabilizing marine metabolite laulimalide and its derivatives:: Synthetic approaches and antitumor activity
J Mulzer et al.
CHEMICAL REVIEWS (2003)
Antimicrotubular drugs binding to vinca domain of tubulin
S Gupta et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2003)
The development of combretastatin A4 phosphate as a vascular targeting agent
DJ Chaplin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity
DE Pryor et al.
BIOCHEMISTRY (2002)
Epothilone and paclitaxel: Unexpected differences in promoting the assembly and stabilization of yeast microtubules
CJ Bode et al.
BIOCHEMISTRY (2002)
New small-molecule tubulin inhibitors
G Bacher et al.
PURE AND APPLIED CHEMISTRY (2001)
Role of formulation vehicles in taxane pharmacology
L van Zuylen et al.
INVESTIGATIONAL NEW DRUGS (2001)
Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli - Production, isolation, physico-chemical and biological properties
F Sasse et al.
JOURNAL OF ANTIBIOTICS (2000)
分享论文
